rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Dyadic International, Inc.

DYAI · Nasdaq

Health CareBiotechnologyNot moving yet

DYAI stood above a rising 150-day average in 4 of the last 52 weekly readings, and has been out of that trend for the last 10 weeks. It is 46.6% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 10
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$250K
Officials’ trades on record
0
Institutions holding
39 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 4 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$406K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months3
Buyers · sellers0 · 1
WhoDidSharesTraded
Francisco Trust Under Agreement Dated February 28, 199610% ownersold2,616at $1.2124 Jul 2026filed 24 Jul 2026
Francisco Trust Under Agreement Dated February 28, 199610% ownersold54,760at $1.3023 Jul 2026filed 24 Jul 2026
Francisco Trust Under Agreement Dated February 28, 199610% ownersold38,016at $1.3322 Jul 2026filed 24 Jul 2026
Francisco Trust Under Agreement Dated February 28, 199610% ownersold15,000at $2.017 Jan 2025filed 6 Jul 2026
Francisco Trust Under Agreement Dated February 28, 199610% ownersold20,000at $1.926 Jan 2025filed 6 Jul 2026
Francisco Trust Under Agreement Dated February 28, 199610% ownersold40,000at $1.9830 Dec 2024filed 6 Jul 2026
Francisco Trust Under Agreement Dated February 28, 199610% ownersold5,100at $1.8024 Dec 2024filed 6 Jul 2026
Francisco Trust Under Agreement Dated February 28, 199610% ownersold41,143at $1.8423 Dec 2024filed 6 Jul 2026
Francisco Trust Under Agreement Dated February 28, 199610% ownersold25,281at $1.8720 Dec 2024filed 6 Jul 2026
Francisco Trust Under Agreement Dated February 28, 199610% ownersold26,340at $2.436 Jun 2024filed 6 Jul 2026
Francisco Trust Under Agreement Dated February 28, 199610% ownerbought558,659at $0.008 Mar 2024filed 6 Jul 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders39+4 on the quarter
New · exited7 · 3
Reported value$4.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 2026928,233$832K00.0%
CHAPIN DAVIS, INC.unchanged · filed 7 Jul 2026888,004$796K00.0%
Apis Capital Advisors, LLCreduced · filed 14 Aug 2026804,882$721K-466,090−36.7%
TRUIST FINANCIAL CORPunchanged · filed 28 Jul 2026326,200$292K00.0%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026250,905$225K-62,603−20.0%
BlackRock, Inc.reduced · filed 7 Aug 2026197,749$177K-77,676−28.2%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 2026139,478$125K00.0%
MARATHON CAPITAL MANAGEMENTunchanged · filed 22 Jul 2026110,000$99K00.0%
Sage Mountain Advisors LLCunchanged · filed 5 Aug 2026106,564$95K00.0%
HighTower Advisors, LLCunchanged · filed 5 Aug 202679,469$71K00.0%
31 Mar 2023 – 30 Jun 2026
263339Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Francisco Trust under agreement dated February 28, 1996 Company insider10% owner · last 24 Jul 20260 · 14
Jack Kaye Company insiderDirector · last 2 Jan 20260 · 0
Joseph P. Hazelton Company insiderPresident & COO · last 2 Jan 20261 · 0
Mark A. Emalfarb Company insiderCEO · last 2 Jan 20260 · 9
Patrick K. Lucy Company insiderDirector · last 2 Jan 20260 · 0
Ping Wang Rawson Company insiderChief Financial Officer · last 2 Jan 20263 · 0
Ronen Tchelet Company insiderVP of Research and Bus. Dvlpmt · last 2 Jan 20260 · 13
Seth Herbst Company insiderDirector · last 2 Jan 20260 · 0
Arindam Bose Company insiderDirector · last 20 Jun 20250 · 0
Michael P. Tarnok Company insiderDirector · last 20 Jun 20250 · 0
Barry Buckland Company insiderDirector · last 11 Jun 20240 · 1
Matthew S. Jones Company insiderManaging Dir of BD & Licensing · last 4 Jan 20210 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202524.9%
Operating profit marginFY 2025 · to 31 Dec 2025-233%
Return on capital employedFY 2025 · to 31 Dec 2025-115%
Research spendFY 2025 · to 31 Dec 202569.7%
Share count trendFY 2025 · to 24 Mar 20260.7%
Cash and equivalentsFY 2025 · to 31 Dec 2025$4.6M

Analyst forecasts

No analyst forecasts yet.